08:00 , Jan 21, 2013 |  BC Week In Review  |  Clinical News

AT13148: Phase I/IIa started

Cancer Research U.K. and its technology transfer arm Cancer Research Technology began an open-label, dose-escalation, U.K. Phase I/IIa trial to evaluate oral AT13148 in about 40 patients with advanced solid tumors. AT13148 was discovered under...
07:00 , Jul 16, 2012 |  BC Week In Review  |  Clinical News

Astex Pharmaceuticals, Cancer Research Technology preclinical data

In mouse models of solid tumors, AT13148 slowed tumor growth in EGFR2 ( HER2 ; ErbB2 ; neu)-positive breast cancer and phosphoinositide 3-kinase (PI3K) alpha mutation BT474-expressing breast cancer, as well as in phosphatase and...
07:00 , Oct 6, 2008 |  BC Week In Review  |  Company News

Astex Therapeutics, Cancer Research UK deal

Cancer Research Technology Ltd., the technology transfer arm of Cancer Research U.K. will conduct early stage development of Astex's AT13148 to treat cancer in exchange for undisclosed royalties. Cancer Research will fund the research and...